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Body-mass index and risk of 22 speciﬁ c cancers: a 
population-based cohort study of 5·24 million UK adults
Krishnan Bhaskaran, Ian Douglas, Harriet Forbes, Isabel dos-Santos-Silva, David A Leon, Liam Smeeth
Summary
Background High body-mass index (BMI) predisposes to several site-speciﬁ c cancers, but a large-scale systematic and 
detailed characterisation of patterns of risk across all common cancers adjusted for potential confounders has not 
previously been undertaken. We aimed to investigate the links between BMI and the most common site-speciﬁ c 
cancers.
Methods With primary care data from individuals in the Clinical Practice Research Datalink with BMI data, we ﬁ tted 
Cox models to investigate associations between BMI and 22 of the most common cancers, adjusting for potential 
confounders. We ﬁ tted linear then non-linear (spline) models; investigated eﬀ ect modiﬁ cation by sex, menopausal 
status, smoking, and age; and calculated population eﬀ ects.
Findings 5·24 million individuals were included; 166 955 developed cancers of interest. BMI was associated with 17 of 
22 cancers, but eﬀ ects varied substantially by site. Each 5 kg/m² increase in BMI was roughly linearly associated with 
cancers of the uterus (hazard ratio [HR] 1·62, 99% CI 1·56–1·69; p<0·0001), gallbladder (1·31, 1·12–1·52; p<0·0001), 
kidney (1·25, 1·17–1·33; p<0·0001), cervix (1·10, 1·03–1·17; p=0·00035), thyroid (1·09, 1·00–1·19; p=0·0088), and 
leukaemia (1·09, 1·05–1·13; p≤0·0001). BMI was positively associated with liver (1·19, 1·12–1·27), colon (1·10, 
1·07–1·13), ovarian (1·09, 1.04–1.14), and postmenopausal breast cancers (1·05, 1·03–1·07) overall (all p<0·0001), but 
these eﬀ ects varied by underlying BMI or individual-level characteristics. We estimated inverse associations with 
prostate and premenopausal breast cancer risk, both overall (prostate 0·98, 0·95–1·00; premenopausal breast cancer 
0·89, 0·86–0·92) and in never-smokers (prostate 0·96, 0·93–0·99; premenopausal breast cancer 0·89, 0·85–0·94). 
By contrast, for lung and oral cavity cancer, we observed no association in never smokers (lung 0·99, 0·93–1·05; oral 
cavity 1·07, 0·91–1·26): inverse associations overall were driven by current smokers and ex-smokers, probably 
because of residual confounding by smoking amount. Assuming causality, 41% of uterine and 10% or more of 
gallbladder, kidney, liver, and colon cancers could be attributable to excess weight. We estimated that a 1 kg/m² 
population-wide increase in BMI would result in 3790 additional annual UK patients developing one of the ten cancers 
positively associated with BMI.
Interpretation BMI is associated with cancer risk, with substantial population-level eﬀ ects. The heterogeneity in the 
eﬀ ects suggests that diﬀ erent mechanisms are associated with diﬀ erent cancer sites and diﬀ erent patient subgroups.
Funding National Institute for Health Research, Wellcome Trust, and Medical Research Council.
Copyright © Bhaskaran et al. Open Access article distributed under the terms of CC BY.
Introduction
Understanding of the eﬀ ects of adiposity on major 
health outcomes has never been more urgent, given the 
rapid rise in obesity worldwide in recent years.1 Research 
has suggested that body-mass index (BMI) is an 
important predictor of cancer risk:2 a Norwegian cohort 
study reported associations with several cancer sites, 
including the thyroid3 and ovaries;4 and the UK Million 
Women Study showed associations between BMI and 
ten of 17 sites investigated.5 Two large reviews brought 
these and many smaller studies together.6,7 In a 
meta-analysis of 221 datasets, strong associations were 
recorded between BMI and cancers of the oesophagus, 
thyroid, colon, kidneys, endometrium, and gallbladder, 
and weaker associations were shown for several other 
sites.7 Increased BMI was negatively associated with 
lung cancer.
However, there are important limitations to the 
evidence base: individual studies have often had 
insuﬃ  cient power, and potential confounders have been 
inconsistently measured across studies; information is 
scarce about the role of factors such as age and smoking 
status that could modify BMI–cancer associations; many 
studies have used self-reported BMI data, which probably 
underestimate true BMI;8 and non-linear associations 
between BMI and cancer risk have seldom been 
investigated.
Our aim was to investigate the links between BMI and 
the most common site-speciﬁ c cancers using BMI and 
outcome data from routinely collected UK primary care 
records. We had the following objectives: to estimate 
BMI associations with a wide range of cancers with 
higher precision than has previously been possible; to 
examine possible non-linear associations between BMI 
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and cancer; to systematically investigate eﬀ ect 
modiﬁ cation by important individual-level factors; and to 
calculate absolute measures of eﬀ ect and thus quantify 
the public health importance of estimated BMI–cancer 
associations.
Methods
Study design and setting
We undertook a cohort study with prospectively collected 
data from the UK Clinical Practice Research Datalink 
(CPRD), which contains computerised primary care 
records from general practitioners who use the Vision IT 
system and have agreed at the practice level to participate 
(covering about 9% of the UK population). CPRD captures 
diagnoses, prescriptions, and tests from primary care, and 
referrals to specialists, hospital admissions, and diagnoses 
made in secondary care, which are typically reported back 
to the general practitioners. CPRD has high validity for a 
range of diagnoses.9 General practitioners record lifestyle 
(eg, smoking status, alcohol use) and anthropometric 
measurements (eg, height, weight); these measurements 
could be recorded at patient registration, opportunistically 
during care, or as deemed clinically relevant by the general 
practitioners. Data collection began in 1987, and we used 
all data to July, 2012.
Participants, exposures, and outcomes
We included all people in CPRD aged 16 years or older 
with BMI data and subsequent eligible follow-up time 
available. BMI was calculated directly from weight and 
height records (weight/height²). We have published 
details on the processing, cleaning, and representativeness 
of CPRD BMI data.10 Exposure was assigned as the 
earliest BMI recorded during research-standard CPRD 
follow-up (ie, follow-up meeting CPRD’s data quality 
criteria). However, to maximise the available follow-up 
time in individuals without a BMI recorded at the 
beginning of research-standard follow-up, we used the 
most recent previous BMI (if available) and time-updated 
it when the ﬁ rst research-standard BMI record became 
available (appendix p 6).These older BMIs were dropped 
in a sensitivity analysis. Other than this speciﬁ c situation, 
we did not time-update BMI during follow-up.
Study entry began 12 months after registration because 
cancers recorded soon after registration could reﬂ ect 
pre-existing or historical disease. Additionally, we 
assigned BMI records as exposure only 12 months after 
their recording, to guard against reverse causality (ie, 
BMI being aﬀ ected by undiagnosed cancer); this period 
was extended to 3 years in a sensitivity analysis. 
Individuals with any record of cancer before study entry 
were excluded, as were those with data inconsistencies 
in important dates (date of birth, start and end of 
follow-up).
To identify outcomes, CPRD clinical records were 
searched for codes showing malignant disease 
(appendix p 1). Our outcomes were the 21 most common 
cancers in the UK (covering 90% of all cancers annually)—
namely female breast, prostate, colon, rectum, lung, 
malignant melanoma, bladder, stomach, oesophageal, 
non-Hodgkin lymphoma, leukaemia, ovary, pancreas, 
multiple myeloma, uterus body, brain and central nervous 
system, liver, kidney, cervix, oral cavity, and thyroid;11 we 
included a 22nd cancer type (gallbladder) because of 
evidence suggesting a link with BMI.7 More than 90% of 
nationally registered cancers can be identiﬁ ed in CPRD 
records, which suggests that it has high sensitivity.12 
Figure 1: Flow diagram showing the creation of the main dataset, reasons for exclusions, and assignment of 
body-mass index (BMI) at study entry
CPRD= Clinical Practice Research Datalink. *When the ﬁ rst available BMI was after start of CPRD follow-up, the 
patient was late-entered into the risk set.
10 038 812 individuals in CPRD with any 
 follow-up aged ≥16  years
6 185 050 individuals remaining
5 366 741 individuals remaining
5 366 639 individuals remaining
5 243 978 in the ﬁnal dataset
Assignment of BMI 
3 853 762 with no BMI records
102 data inconsistencies in
 important dates (patients
 apparently aged >110 years
 during follow-up)
122 661 had a cancer diagnosis
 before cohort entry date
2 051 563 had exposure initially assigned with a 
 BMI recorded before CPRD follow-up. 
 Median gap between BMI record and start
 of follow-up was 2·0 years (IQR 0·6–4·5)
1 237 848 had exposure status updated at ﬁrst
 available BMI measured during 
 CPRD follow-up
3 192 415 had exposure initially assigned with a BMI
 recorded at CPRD entry or during
 follow-up. Median time from start of CPRD
 follow-up to BMI record used to assign
 exposure was 50 days (IQR 4 days to
 2·9 years)*
818 309 had follow-up ended
 during 12 month exclusion
 period following BMI
 record, leaving no eligible
 follow-up time
See Online for appendix
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Analyses of female breast cancer were stratiﬁ ed a priori by 
menopausal status on the basis of previous evidence of 
diﬀ erent BMI eﬀ ects.5,7 At the ﬁ rst diagnosis of any cancer 
(including sites not investigated here), patients were 
censored for other cancer sites, because of diﬃ  culty in 
separating metastatic from second de-novo cancers, and 
the diﬀ erent risk proﬁ le of cancer survivors. The detailed 
algorithms used to process and derive variables in our 
analysis are available on request from the corresponding 
author.
Statistical analysis
People were followed-up from study entry until the 
earliest of: ﬁ rst cancer diagnosis (any site), death, transfer 
out of CPRD, or last data collection date for the practice. 
We censored 30 days after the ﬁ rst record of hysterectomy 
for uterine and cervical cancer, and after bilateral 
oophorectomy for ovarian cancers (we allowed 30 days to 
capture cancers related to, or detected at, the procedure).
To relate BMI to risk of each cancer, we ﬁ tted Cox 
models with attained age as the underlying timescale. We 
Underweight
(BMI <18·5 kg/m²)
Normal BMI
(18·5–25 kg/m²)
Overweight and obese
(BMI ≥25 kg/m²)
Overall
N 165 530 2 571 573 2 506 875 5 243 978
Person-years from BMI date to end of follow-up
Mean (SD) 6·2 (4·8) 7·4 (5·4) 7·6 (5·2) 7·5 (5·3)
Median (IQR) 4·7 (2·4–8·9) 5·9 (2·9–11·1) 6·4 (3·2–11·1) 6·0 (3·0–11·0)
Range 1·0–24·5 1·0–24·5 1·0–24·6 1·0–24·6
Total person-years included* (millions) 0·869 16·451 16·521 33·841
Age (years)
Median (IQR) 25·5 (19·5–39·4) 33·4 (24·6–48·4) 43·6 (31·5–57·6) 37·9 (27·0–53·7)
Sex
Male 49 107 (29·7) 1 038 167 (40·4) 1 292 046 (51·5) 2 379 320 (45·4)
Female 116 423 (70·3) 1 533 406 (59·6) 1 214 829 (48·5) 2 864 658 (54·6)
Smoking status
Never smoker 75 464 (45·6) 1 236 201 (48·1) 1 167 989 (46·6) 2 479 654 (47·3)
Current smoker 69 580 (42·0) 961 893 (37·4) 830 733 (33·1) 1 862 206 (35·5)
Ex-smoker 17 364 (10·5) 348 455 (13·6) 487 093 (19·4) 852 912 (16·3)
Missing 3122 (1·9) 25 024 (1·0) 21 060 (0·8) 49 206 (0·9)
Alcohol use†
Non-drinker 33 778 (20·4) 315 463 (12·3) 303 750 (12·1) 652 991 (12·5)
Current drinker (light) 80 323 (48·5) 1 519 351 (59·1) 1 401 081 (55·9) 3 000 755 (57·2)
Current drinker (moderate) 8133 (4·9) 243 569 (9·5) 282 474 (11·3) 534 176 (10·2)
Current drinker (heavy) 4499 (2·7) 64 177 (2·5) 70 285 (2·8) 138 961 (2·6)
Current drinker (amount not known) 6414 (3·9) 96 109 (3·7) 98 992 (3·9) 201 515 (3·8)
Ex-drinker 10 043 (6·1) 136 928 (5·3) 174 413 (7·0) 321 384 (6·1)
Missing 22 340 (13·5) 195 976 (7·6) 175 880 (7·0) 394 196 (7·5)
Previous diabetes 1965 (1·2) 46 330 (1·8)  143 033 (5·7) 191 328 (3·6)
Index of multiple deprivation quintile
1 (least deprived) 20 526 (12·4) 390 322 (15·2) 331 347 (13·2) 742 195 (14·2)
2 42 175 (25·5) 738 004 (28·7) 697 055 (27·8) 1 477 234 (28·2)
3 46 881 (28·3) 726 831 (28·3) 734 314 (29·3) 1 508 026 (28·8)
4 35 950 (21·7) 487 334 (19·0) 496 929 (19·8) 1 020 213 (19·5)
5 (most deprived) 19 998 (12·1) 229 082 (8·9) 247 230 (9·9) 496 310 (9·5)
Calendar year
<1989 2139 (1·3) 42 548 (1·7) 36 460 (1·5) 81 147 (1·5)
1990–94 32 163 (19·4) 666 646 (25·9) 549 264 (21·9) 1 248 073 (23·8)
1995–99 34 157 (20·6) 584 901 (22·7) 547 819 (21·9) 1 166 877 (22·3)
2000–04 40 390 (24·4) 572 579 (22·3) 618 579 (24·7) 1 231 548 (23·5)
2005–09 46 310 (28·0) 584 572 (22·7) 621 717 (24·8) 1 252 599 (23·9)
≥2010 10 371 (6·3) 120 327 (4·7) 133 036 (5·3) 263 734 (5·0)
Data are n (%) unless otherwise stated. Time-varying characteristics are at date of ﬁ rst eligible BMI measurement. *After excluding ﬁ rst 12 months after registration, and any 
time without a mature (≥12 months old) BMI measurement available. †Light, moderate, or heavy current drinking were assigned when either the general practitioner had 
recorded a Read code with one of these terms, or when the units per day were recorded as 1–2 (light), 3–6 (moderate), 7+ (heavy).
Table 1: Characteristics of individuals included in the study, overall and by body-mass index (BMI) category
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used the same systematic analysis strategy consistently 
across cancer sites. We initially adjusted for age at BMI 
record and sex only, and considered BMI in WHO 
categories.13 We then ﬁ tted fully adjusted models, with 
BMI as a continuous linear term to estimate the average 
eﬀ ect of a 5 kg/m² increase in BMI on cancer risk; we 
controlled for the following covariates at time of the BMI 
record(s): age (three-knot restricted cubic spline to allow 
for non-linearity); smoking status (never smoker, current 
smoker, ex-smoker); alcohol use (non-drinker, current 
drinker [light, moderate, heavy, unknown], ex-drinker); 
previous diabetes diagnosis; index of multiple deprivation 
(in quintiles, a measure of socioeconomic status);14 
calendar period (<1989, 1990–94, 1995–99, 2000–04, 
2005–09, ≥2010); and stratiﬁ ed by sex. The assumed 
causal framework implied by our choice of covariate 
adjustments is shown in the directed acyclic graph15 
(appendix p 7). Because of concerns about residual 
confounding by smoking we repeated this analysis 
(post-hoc) restricting to never smokers.
Then, a restricted cubic spline basis for BMI was used 
to investigate possible non-linearity in each BMI–cancer 
association (appendix p 1). Eﬀ ect modiﬁ cation was 
assessed by introducing interaction terms (one at a time) 
between the BMI spline basis variables and sex, smoking 
status, menopausal status (time-updated, postmenopausal 
deﬁ ned as aged 50 years or more, which is the approximate 
average age at menopause in the UK, or ever on hormone 
replacement therapy), and present age (time-updated, 
16–49, 50–64, 65–74, ≥75 years, categories chosen to divide 
total cancer events into approximate quartiles). If 
(post-hoc) there was a threshold eﬀ ect, it was estimated 
and summarised by ﬁ tting piecewise linear models across 
all possible threshold values and using the one giving the 
highest likelihood.
For cancers positively associated with BMI, population 
attributable risks were calculated by ﬁ tting a 
three-category BMI variable (BMI <18·5, 18·5–25, 
≥25 kg/m²), and combining estimated hazard ratios 
(HRs) for overweight and obesity with published national 
overweight and obesity prevalence (Health Survey for 
England 2010); we accounted for a potentially diﬀ erent 
cancer risk in underweight individuals when calculating 
population attributable risks (appendix p 2).16 Projected 
Figure 2: Forest plot of hazard ratios (HR) for each cancer per 5 kg/m² 
increase in body-mass index (BMI), from models with BMI ﬁ tted as a linear 
eﬀ ect
Number of incident cancer cases in never smokers only were: oral cavity (302); 
oesophagus (1858); stomach (1320); colon (6115); rectum (2623); liver (699); 
gallbladder (133); pancreas (1525); lung (2674); malignant melanoma (4477); 
breast—premenopausal (3109); breast—postmenopausal (14 833); cervix (535); 
uterus (1555); ovaries (1864); prostate (10 634); kidney (776); bladder (2687); 
brain and central nervous system (CNS) (1359); thyroid (478); non-Hodgkin 
lymphoma (3212); multiple myeloma (1441); and leukaemia (2685). HRs 
estimated using a separate model for each cancer with linear BMI term, adjusted 
for age, diabetes status, smoking, alcohol use, socioeconomic status, calendar 
year, and stratiﬁ ed by sex; p values from Wald tests on the linear BMI term in 
each adjusted model.
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increases in the number of cancers were estimated under 
a scenario of a population-wide 1 kg/m² BMI increase as 
follows: we ﬁ rst replicated our non-linear Cox models 
with Poisson modelling with additional adjustment for 
time-updated age, to allow direct prediction of event 
numbers; we then randomly sampled (with replacement) 
from the main study population a cohort with the same 
age and sex distribution as the UK population; we then 
increased all BMIs by 1 kg/m² and predicted from our 
models the extra number of cancer events; and ﬁ nally the 
percentage increase was applied to present UK cancer 
incidences to obtain the projected number of extra 
cancers per year. CIs were estimated by bootstrapping.
We excluded people with missing smoking 
(49 206/5·24 million [0·9%]) and alcohol status 
(394 196/5·24 million [7·5%]). Since 22 cancer outcomes 
were considered, all CIs are presented at the 99% level.
Model checking and sensitivity analyses
The analysis of eﬀ ect modiﬁ cation by present age 
implicitly checks for non-proportional hazards for the 
BMI variable; we checked for non-proportional hazards 
in other variables by testing for a zero slope in the 
scaled Schoenfeld residuals over time.17 In sensitivity 
analyses, we reinstated the 12 month follow-up after a 
BMI recording into the analysis to check the eﬀ ect of 
this exclusion criterion; extended the exclusion period 
after a BMI record to 3 years; restricted to patients who 
had a BMI record soon (<12 months) after registration 
because these BMI measurements were probably 
administratively rather than clinically motivated; 
dropped BMIs recorded before the start of research 
standard follow-up; used hospital episodes and cause of 
death data to detect cancers that might have been 
missed in CPRD; adjusted for general practitioner 
contact in the ﬁ rst 12 months of CPRD follow-up (as a 
binary variable), to account for potential selection 
(collider stratiﬁ cation) bias18 because of restricting to 
those with BMI measured (appendix p 8); adjusted for 
detected non-proportional hazards by adding 
interactions with present age; and restricted the 
analysis to recent calendar periods in which BMI 
completeness in CPRD was higher so any selection 
biases due to missing BMI would be expected to have 
less eﬀ ect. Finally, post-hoc, we re-estimated the 
association between BMI and postmenopausal breast 
and ovarian cancers, censoring at ﬁ rst hormone 
replacement therapy use, in case such treatment 
masked or diluted BMI–cancer associations. We 
repeated the analysis of liver cancer with multiple 
imputations to account for missing alcohol data 
(ﬁ ve imputations, multinomial logistic imputation 
model including all terms from our substantive model).
The study was approved by the London School of 
Hygiene and Tropical Medicine Ethics Committee. The 
prespeciﬁ ed scientiﬁ c protocol (appendix pp 16–25) was 
Figure 3: Association between body-mass index (BMI) and speciﬁ c cancers, allowing for non-linear eﬀ ects, with 99% CIs
The reference BMI for these plots (with HR ﬁ xed as 1·0) was 22 kg/m². Separate models were ﬁ tted for each cancer type, each with a restricted cubic spline for BMI (knots placed at equal percentiles of 
BMI), adjusted for age, calendar year, diabetes status, alcohol use, smoking (all at time of BMI recording), socioeconomic status (index of multiple deprivation), and stratiﬁ ed by sex. HR=hazard ratio.
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p-overall=0·13
p-non-linear=0·64
Brain and CNS (C71–72)
p-overall=0·010
p-non-linear=0·11
Thyroid (C73)
p-overall=0·025
p-non-linear=0·060
Non–Hodgkin lymphoma (C82–85)
p-overall=0·28
p-non-linear=0·54
Multiple myeloma (C90)
p-overall<0·0001
p-non-linear=0·38
Leukaemia (C91–95)
For the Health Survey for 
England 2010 see http://www.
hscic.gov.uk/pubs/hse10trends
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approved by the Independent Scientiﬁ c Advisory 
Committee for MHRA Database Research in July, 2012. 
Data analysis was done in Stata version 12, on a 
high-performance computer cluster.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Of 10·04 million individuals aged 16 years or older in 
CPRD, 6·19 million had any BMI measurement recorded. 
Of these, 5·24 million (84%) had eligible follow-up time 
and no previous cancer diagnosis and were included in 
the study (ﬁ gure 1); follow-up ended a mean of 7·5 years 
(SD 5·3) after the ﬁ rst eligible BMI measurement. Mean 
BMI was 25·5 kg/m² (SD 4·9). Compared with the overall 
CPRD population, those included were more likely to be 
female (2·86 million/5·24 million [54·6%] vs 
5·29 million/10·04 million [52·7%] overall), and to have 
an earlier year of birth (median 1962 [IQR 1946–1974] vs 
1964 [1946–1977] overall). Table 1 and appendix (p 3) 
describe the characteristics of those included and 
excluded in the analysis.
201 504 of 5·24 million individuals (3·8%) developed 
any cancer and 166 955 (3·2%) developed one of the 
22 cancers of interest during follow-up. Appendix (p 4) 
presents the numbers for each cancer site and relative 
risks by WHO obesity category adjusted for age and sex. 
For 13 of 22 cancers, one or more of the overweight and 
obese categories seemed to be associated with higher 
risk compared with normal weight, but the size of the 
eﬀ ect and patterns across BMI categories varied by site 
(appendix p 4). Underweight seemed to be associated 
with increased risk of oral cavity, oesophageal, stomach, 
and lung cancers, but decreased risk of postmenopausal 
breast and prostate cancers (appendix p 4).
With BMI included as a linear eﬀ ect, and adjusting for 
all potential confounders, each 5 kg/m² increase in BMI 
was associated with a large increase in risk of cancer of 
the uterus (HR 1·62, 99% CI 1·56–1·69; ﬁ gure 2). There 
were also large increases in risk (HR >1·1 per 5 kg/m²) 
for cancers of the gallbladder, kidney, and liver, and small 
increases in risk for colon, cervical, thyroid, ovarian, and 
postmenopausal breast cancers and leukaemia (ﬁ gure 2). 
Net inverse associations were estimated for oral cavity, 
lung, premenopausal breast, and prostate cancers, but 
restricting to never smokers, the inverse association with 
lung and oral cavity cancers disappeared (ﬁ gure 2). There 
was a positive association between BMI and oesophageal 
and stomach cancers in never smokers; other eﬀ ect 
estimates were similar in never smokers and the full 
population (ﬁ gure 2).
Figure 3 shows the estimated shape of each BMI–cancer 
association, allowing for non-linearity. These non-linear 
models were reﬁ tted with interaction terms to assess 
possible modiﬁ cation by sex, smoking status, menopausal 
status, and present age (appendix pp 9–12). These analyses 
showed overall evidence of association between BMI and 
Figure 4: Modelled associations between body-mass index (BMI) and colon, liver, breast, ovarian, and 
prostate cancers and malignant melanoma, including detected non-linearities and eﬀ ect modiﬁ cation
Curves for each cancer type estimated from models with BMI ﬁ tted as a spline, adjusted for age, calendar year, 
diabetes status, smoking, alcohol use, socioeconomic status (index of multiple deprivation). Stratiﬁ ed curves were 
produced by adding interaction terms with the BMI spline basis. For estimated eﬀ ect modiﬁ cation by sex, 
smoking, menopausal status, and present age for all cancer types, see appendix pp 9–12. Estimated HRs per 
5 kg/m² derived from best ﬁ tting piecewise linear or linear model (with Akaike information criterion used to select 
optimal knots or thresholds). HR=hazard ratio.
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17 of 22 cancers studied (all except rectum, bladder, brain 
and CNS, non-Hodgkin lymphoma, multiple myeloma), 
and evidence of non-linearity or eﬀ ect modiﬁ cation for 
ten cancers (ﬁ gure 3; appendix pp 9–12). Associations 
between BMI and both colon and liver cancer were more 
marked in men than women: in men, higher BMI was 
associated with substantially increased risk but only if 
BMI was above 22 kg/m², whereas in women more 
modest increases in risk were recorded with no evidence 
against linearity (ﬁ gure 4). Increases in ovarian cancer risk 
with BMI were larger in premenopausal than post-
menopausal women. As expected, there were diﬀ erences 
by menopausal status for breast cancer: BMI was positively 
associated with both premenopausal and postmenopausal 
breast cancers at the lower end of the BMI range 
(<22 kg/m²), whereas above this value, risk of pre-
menopausal breast cancer reduced markedly with 
increasing BMI (ﬁ gure 4). A similar peaked pattern was 
noted for prostate cancer and malignant melanoma in 
men (with risk peaking at BMI 27 kg/m² for prostate 
cancer and 24 kg/m² for malignant melanoma; ﬁ gure 4).
For lung, oral cavity, and stomach cancers, low BMI was 
associated with increased risk but this risk was driven by 
current smokers and ex-smokers and was attenuated or 
disappeared in never smokers (ﬁ gure 5). Smoking seemed 
to drive the apparent eﬀ ect modiﬁ cation by sex and age for 
these cancers (p for interaction >0·1 in each case when 
restricted to never smokers; appendix pp 9, 12). For 
oesophageal cancer, there was evidence of eﬀ ect 
modiﬁ cation by sex, smoking, and age (appendix pp 9–12).
With the assumption that the recorded associations 
were causal, we estimated that 41% of cancers of the 
uterus and more than 10% of gallbladder, kidney, liver, 
and colon cancers are attributable to overweight and 
obesity, and that a 1 kg/m² population-wide increase in 
BMI would lead to 3790 extra patients developing one of 
the ten cancers that had a net positive association with 
BMI (113 928 projected per year in total compared with 
110 138 at present; table 2). For the two cancers overall 
inversely associated with BMI even in never-smokers, the 
corresponding projected decreases in numbers of new 
diagnoses per year were modest (prostate: projected 
change –72, 99% CI –159 to 15; premenopausal breast: 
–128, –147 to –110).
Our main ﬁ ndings were robust to a range of sensitivity 
analyses; estimated eﬀ ect sizes were similar and in all 
cases, CIs included the point estimate from the main 
analysis (appendix pp 5, 13–15).
Discussion
In the largest single dataset assembled so far for this 
purpose, we recorded associations between BMI and 17 of 
22 cancers studied, but eﬀ ects varied substantially by 
cancer type, in both direction and size. Higher BMI was 
roughly linearly related with increased risk of uterine, 
gallbladder, kidney, cervical, thyroid cancers, and 
leukaemia. Overall positive associations were recorded 
between BMI and liver, colon, ovarian, and 
postmenopausal breast cancers, but these associations 
were non-linear (the eﬀ ect of BMI varying across the BMI 
range) or modiﬁ ed by individual level factors. BMI had a 
net inverse association with risk of premenopausal breast 
and prostate cancers; for lung and oral cavity cancers, an 
overall inverse association seemed to be driven by 
smoking and was not observed in never smokers.
Figure 5: Associations between body-mass index and oral, stomach, and 
lung cancers with eﬀ ect modiﬁ cation by smoking status
Curves for each cancer type estimated from models with BMI ﬁ tted as a spline, 
interaction terms between smoking status and spline basis, adjusted for age, 
calendar year, diabetes status, alcohol use, socioeconomic status (index of 
multiple deprivation), and stratiﬁ ed by sex. p values for eﬀ ect of BMI in never 
smokers=0·62 for oral cavity cancer, 0·16 for stomach cancer, and 0·18 for lung 
cancer. Estimated curves by smoking status for all cancer types are presented in 
appendix p 10. Pinteraction=p value for interaction. HR=hazard ratio.
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 Renehan and colleagues7 summarised the evidence 
about BMI and cancer in their landmark 2008 systematic 
review and meta-analysis. In our study we have added to 
this evidence by systematically investigating non-linearity 
and eﬀ ect modiﬁ cation by individual factors. These 
analyses mean that we were able to characterise 
relationships between BMI and a wide range of individual 
cancers in greater detail than has previously been 
possible. To our knowledge, ours is the ﬁ rst large-scale 
study of its kind to estimate public health eﬀ ects of 
BMI–cancer associations across a range of sites.
For the six cancers positively and linearly associated 
with BMI, our eﬀ ect sizes were broadly consistent with 
previous studies (appendix pp 27–30). We did not ﬁ nd 
strong evidence of non-linearity in the association 
between BMI and cancer of the uterus, although our 
estimated curve was not incompatible with a larger eﬀ ect 
at higher BMI, as was reported in one previous 
meta-analysis.19 There was strong evidence of a modest 
positive association of BMI with cervical cancer, a site 
which was not included in the meta-analysis by Renehan 
and colleagues:7 the estimated 10% increase in risk per 
5 kg/m² was consistent with the CIs from the three other 
studies we identiﬁ ed in our updated systematic review 
that investigated this site (panel; appendix p 29),5,20,21 
although in only one of these did CIs for the 
HR exclude 1.21 We detected no strong evidence of 
associations between BMI and cancers of the rectum, 
brain, CNS, and bladder, non-Hodgkin lymphoma, or 
multiple myeloma, and only weak evidence for cancer of 
the pancreas; for some of these sites, small associations 
have been reported previously, but these were consistent 
with our CIs (appendix pp 27–30).
For the other ten cancers, we conﬁ rmed previously 
identiﬁ ed links with BMI, but we identiﬁ ed non-linear 
relationships or important eﬀ ect modiﬁ cations that had 
not previously been characterised in detail. The modest 
overall eﬀ ect of BMI on ovarian cancer risk matched that 
in previous studies,7,22 but we noted a much larger eﬀ ect 
in premenopausal compared with postmenopausal 
women; this ﬁ nding contrasts with those of a 
meta-analysis which showed no diﬀ erence when 
combining six previous studies that stratiﬁ ed by 
menopausal status, although a weakness was the diﬀ erent 
deﬁ nitions of menopausal status used across the 
constituent studies.22 Nevertheless, given the conﬂ icting 
evidence, this ﬁ nding of eﬀ ect modiﬁ cation needs to be 
replicated (or otherwise) elsewhere.
BMI has been inversely associated with premenopausal 
and positively associated with postmenopausal breast 
cancer,5 which we also noted, but incorporating 
non-linearity showed a more nuanced picture: risk of 
premenopausal breast cancer seemed to peak at 22 kg/m² 
then dropped as BMI increased further. A similar pattern 
was evident for malignant melanoma and prostate cancer 
in men, which could explain why previous studies 
treating BMI as a linear term have estimated only modest 
or inconsistent associations with these cancers.7 This 
might reﬂ ect a real non-linear biological association, but 
another explanation is that diagnoses could be delayed or 
missed in people who are overweight and obese, which is 
supported by the ﬁ nding that BMI correlates inversely 
with localised prostate cancer and positively with 
advanced disease.23
The inverse relationship between BMI and lung cancer 
concurs with other research,7 and we noted a similar 
pattern for oral cavity cancer—the eﬀ ect was 
predominantly at the lower end of the BMI scale, and was 
evident only in current smokers or ex-smokers (as in 
another recent study of lung cancer24). Confounding by 
amount of smoking is the most likely explanation (low 
BMI acting as a proxy for heavier smoking) because we 
had only crudely categorised smoking data. By contrast, 
high risk of oesophageal cancer in underweight 
individuals was evident even in never smokers. However, 
we had no information about oesophageal cancer type; 
evidence suggests that BMI could have opposite eﬀ ects on 
adenocarcinoma versus squamous cell carcinoma,7 which 
might have resulted in the U-shaped association overall. 
Another explanation is residual confounding by amount 
of drinking: heavy drinking could be associated with both 
underweight and overweight in diﬀ erent individuals.
Heterogeneity in the eﬀ ects of BMI suggests that there 
are diﬀ erent mechanisms or combinations of 
mechanisms associated with diﬀ erent sites and in 
diﬀ erent patient subgroups. Several pathways have been 
proposed; changes in hormone metabolism, particularly 
with regard to insulin, insulin-like growth factors, and 
New cases per 
year (UK)*
n (%) cases attributable 
to overweight and 
obesity
Projected extra cases per year 
with a 1 kg/m² population-wide 
increase in BMI (99% CI)
Colon (C18) 26 725 2970 (11·1%) 559 (519–598)
Liver (C22) 4241 661 (15·6%) 145 (135–154)
Gall bladder (C23) 660 134 (20·3%) 36 (35–37)
Breast (post-
menopausal, C50)
39 812 2035 (5·1%) 1441 (1417–1465)
Cervix (C53) 2851 214 (7·5%) 51 (50–53)
Uterus (C54–55) 8288 3384 (40·8%) 806 (784–829)
Ovaries (C56) 7011 512 (7·3%) 125 (118–133)
Kidney (C64) 9639 1597 (16·6%) 428 (414–442)
Thyroid (C73) 2654 51 (1·9%) 49 (48–51)
Leukaemia (C91–95) 8257 522 (6·3%) 150 (138–163)
Attributable cases and percentage based on models for each cancer with a three-category BMI variable (underweight, 
normal, or overweight and obese), adjusted for age, diabetes status, smoking, alcohol use, socioeconomic status, 
calendar year, and stratiﬁ ed by sex; attributable cases were calculated separately for men and women and then 
combined; we assumed the prevalence of overweight including obese to be 65% in men and 58% in women (Health 
Survey for England 201016). Further details on our method for these calculations are given in appendix (p 2). Projected 
extra cases calculated with ﬁ tted Poisson models with non-linear BMI splines to predict proportion of extra cases in an 
artiﬁ cial population sampled from the original cohort to replicate the age and sex structure of the UK population, with 
all BMIs increased by 1 kg/m², and applying proportionate increase to the annual number of UK cases (*Cancer Research 
UK cancer statistics11); 99% CIs are from a bootstrapping procedure.
Table 2: Estimated UK population eﬀ ects for cancers with evidence of a net positive association with 
body-mass index (BMI)
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sex hormones, have all been implicated, as have 
adipokines (signalling proteins secreted by adipose 
tissue),25 but the precise roles of these mechanisms and 
the interactions between them are not completely 
understood. The diabetes-associated increase in mortality 
from certain cancers seemed to persist after adjustment 
for BMI in one study,26 suggesting that BMI might be 
upstream of diabetes and glycaemia as part of one causal 
chain. Large-scale biobank data linked to long-term 
outcomes might eventually help to further clarify these 
multiple potential pathways.
Our study has considerable strengths. We used a large 
data source to estimate associations with unprecedented 
precision and power; we applied a consistent 
methodological approach to examine BMI eﬀ ects across 
cancer sites, including systematic investigation of 
non-linearity and eﬀ ect modiﬁ cation. The validity of 
CPRD diagnosis data has been established in general,9 
and for cancer in particular (>90% of CPRD cancers 
conﬁ rmed from other sources, >90% of nationally 
registered cancers present in CPRD).12,27 Although some 
outcome misclassiﬁ cation was inevitable, the eﬀ ect on 
our results was probably small, and an additional 
sensitivity analysis using hospital and death certiﬁ cate 
data to capture cancers that might have been missed in 
CPRD gave similar results to our main analysis (appendix 
p 13). CPRD patients broadly represent the wider 
population28 and are not restricted on age or other factors, 
suggesting good generalisibility to the UK population 
and to comparable countries. Our ﬁ ndings were robust 
in a wide range of sensitivity analyses.
There are important limitations. Individuals without 
BMI data were not included; the decision to measure 
BMI in primary care might be related to the patient’s 
apparent weight or their health status, introducing the 
potential for selection bias in our HRs and projections of 
public health eﬀ ect. We already reported (allowing for 
diﬀ erences in age and sex) that those with up-to-date 
BMI data in CPRD had mean BMI and obesity prevalence 
close to that expected based on representative 
population-based survey data,10 suggesting that those 
with complete data in CPRD were not substantially 
diﬀ erent in terms of BMI to the broader population. We 
were empirically reassured against serious selection bias 
by the consistency of our results with previous research, 
including cohort studies with complete BMI information 
(appendix pp 27–30). In a sensitivity analysis, we used 
only BMIs recorded within 12 months of general 
practitioner registration (because they would have 
probably been recorded for administrative and not health 
reasons) and obtained similar results (appendix p 13). In 
a further sensitivity analysis, we increasingly restricted to 
more recent follow-up when BMI completeness was 
higher (including the period from 2005 onwards during 
which BMI recording by general practitioners was 
ﬁ nancially incentivised through the UK Quality and 
Outcomes Framework), and recorded very little change 
in our estimates (appendix p 14). To induce selection 
bias, having a BMI measurement would need to be 
related to both BMI and later cancer risk; this could be 
the case if general practitioner attenders tend to have 
diﬀ erent cancer risk (appendix p 8), or indeed a diﬀ erent 
probability of cancer being diagnosed (eg, through better 
access to screening services), but a sensitivity analysis 
adjusting for this had no material eﬀ ect on the 
conclusions. Our use of complete case analysis to assess 
missing BMI data would be valid providing that the 
probability of having BMI recorded is independent of the 
outcome conditional on covariates;29 more intuitively, the 
BMI–cancer relation should be similar between included 
and excluded individuals (after adjustment for our 
covariate set). We had no a-priori reason to doubt this 
assumption, and we are reassured that our main 
conclusions are unlikely to have been seriously aﬀ ected 
by bias due to missing BMI measurements.
Panel: Research in context
Systematic review
The most relevant summary of the literature on BMI and cancer risk was a 2008 systematic 
review published in The Lancet examining associations between BMI and several cancer 
sites, and diﬀ erences in these associations by sex.7 To update this Review, we searched 
Medline for reports published in any language since 2008, relating BMI to these cancers, 
with the same search keywords described by the authors (terms referring to bodyweight 
combined with terms for each cancer site). We used a similar search strategy to look for 
research on BMI and bladder, brain and central nervous system, cervical, and oral cavity 
cancers, which were not in the 2008 review. The search was supplemented with hand 
searches of reference lists of relevant papers. We included studies of prospectively collected 
data, in which BMI was treated as a continuous exposure and one or more of the cancers of 
interest were included as outcomes. We excluded studies in which only BMI categories were 
considered. We rescaled all reported linear eﬀ ects to a 5 kg/m² BMI increase. We identiﬁ ed 
28 studies to supplement Renehan and colleagues’ systematic review (appendix p 26). The 
main features and ﬁ ndings of these studies are reported by cancer site in appendix 
(pp 27–30) and compared with our own ﬁ ndings. The published evidence so far suggests 
associations between BMI and a cancer that diﬀ er widely by cancer site in both size and 
character. We identiﬁ ed very few data for possible non-linearities. Eﬀ ect modiﬁ cation by sex 
was examined in a few studies, and most ﬁ ndings showed a larger eﬀ ect on colon cancer in 
men than women; information was scarce across the range of cancers on eﬀ ect 
modiﬁ cation by smoking, menopausal status, and age. We did not identify any studies that 
reported BMI associations with oral cavity cancer.
Interpretation
Our data suggest wide-ranging associations between BMI and cancer that vary by cancer 
site; the linear eﬀ ects we estimated were consistent with those that have been reported 
previously (when available). Our study seems to be the ﬁ rst to have systematically 
investigated non-linearity and the role of individual-level factors (sex, smoking, 
menopausal status, and age) across a wide range of cancers, allowing us to better 
understand the relationship between BMI and cancer risk; for ten of 22 cancers we 
detected important non-linearity or eﬀ ect modiﬁ cation. The use of a large data source 
enabled us to include cancers that are not reported in the literature on BMI and cancer 
risk, and to provide statistically precise eﬀ ect estimates conﬁ rming associations between 
BMI and liver and ovarian cancers, in which previously available conﬁ dence intervals were 
too wide to be conclusive. Our absolute estimates of population eﬀ ect emphasised the 
importance of BMI in driving the incidence of several cancers.
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A second important limitation is the potential for 
residual confounding. Despite adjustment for smoking 
status (which itself could have been misclassiﬁ ed to 
some extent30), there was probably confounding by 
amount smoked, although restricting to never smokers 
gave similar estimates to the adjusted analysis in the 
full population for all but four strongly smoking-related 
cancers (lung, oral cavity, stomach, oesophageal). 
Alcohol status was likely to be self-reported to the 
general practitioner (prone to misclassiﬁ cation), and 
information was scarce about the amount of drinking. 
We had no information about physical activity31 
(although its eﬀ ects on cancer risk might be in part 
mediated through BMI itself ), on female reproductive 
factors such as parity and age at ﬁ rst birth, or on 
potentially important infections (eg, hepatitis B and C 
for liver cancer). Our outcome data were insuﬃ  ciently 
detailed to investigate potentially important diﬀ erences 
between cancer subtypes, in particular for oesophageal 
cancer (adenocarcinoma vs squamous cell),7 breast 
cancer (by receptor status),32 non-Hodgkin lymphoma 
(follicular vs diﬀ use large B-cell),33 and colon cancer 
(microsatellite stable vs instable,34–37 or distal vs 
proximal38,39). We examined only BMI associations with 
ﬁ rst cancer and censored follow-up at this point, so our 
study does not provide information about associations 
between BMI and risk of second or subsequent cancers; 
furthermore, this censoring could introduce bias if 
certain cancers tend to be aﬀ ected by BMI sooner than 
others, but since 92% of individuals with a cancer 
diagnosis had only one such diagnosis, censoring is 
unlikely to have had any substantial eﬀ ect. Finally, we 
had no data for important measures of adiposity other 
than BMI.
There is no systematic analysis of non-linearity and 
eﬀ ect modiﬁ cation across a wide range of cancer sites 
with which to directly compare our ﬁ ndings (panel); 
this emphasises the novelty of our study but means that 
new ﬁ ndings from such analyses will need to be 
reproduced by others before they can be considered 
deﬁ nitive.
Assuming the relationships to be causal, many cancers 
are attributable to overweight and obesity. Even within 
normal BMI ranges, higher BMI was associated with 
increased risk of some cancers, accentuating the public 
health implications in view of the overall increase in 
population BMI distributions in several countries. We 
estimated that a 1 kg/m² population increase in mean 
BMI would lead to 3790 additional patients in the UK 
each year developing one of the ten cancers that were 
overall positively associated with BMI. To put this in 
context, based on data from 2003 to 2010, mean BMI in 
England has been increasing at a rate equivalent to a 
1 kg/m² increase taking around 12 years.16 Our data 
strengthen the rationale to assess and implement 
strategies aimed at stopping these trends and mitigating 
their public health eﬀ ects.
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